Conference Coverage

Osteoprotegerin ups risk of vascular events in type 1 diabetes

Publish date: July 22, 2013

 

AT THE ANNUAL ADA SCIENTIFIC SESSIONS

pwendling@frontlinemedcom.com

Pages

Recommended Reading

FDA panels revisit rosiglitazone's cardiovascular safety
MDedge Endocrinology
ACCORD: Insulin dose not implicated in excess CV deaths
MDedge Endocrinology
A third of CHD patients may undergo unnecessary lipid testing
MDedge Endocrinology
Empagliflozin improves cardiovascular risk factors in T2DM
MDedge Endocrinology
Twice daily regimen eases aspirin resistance in diabetes
MDedge Endocrinology
FDA warns about serious GI symptoms with olmesartan
MDedge Endocrinology
Low vitamin D effects on CHD risk vary by race
MDedge Endocrinology
Roche halts studies of experimental type 2 diabetes drug
MDedge Endocrinology
Excessive visceral fat linked to increased risk of CVD, cancer
MDedge Endocrinology
Longer duration of obesity linked to coronary calcification
MDedge Endocrinology